cfz533
Showing 1 - 9 of 9
Type 1 Diabetes Trial in Worldwide (CFZ533, Placebo)
Recruiting
- Type 1 Diabetes Mellitus
- CFZ533
- Placebo
-
Edegem, Antwerpen, Belgium
- +16 more
Aug 23, 2022
Lupus Nephritis Trial in Worldwide (CFZ533, Placebo)
Active, not recruiting
- Lupus Nephritis
- CFZ533
- Placebo
-
Ciudad Autonoma de Bs As, Buenos Aires, Argentina
- +20 more
Aug 23, 2022
Systemic Lupus Erythematosus (SLE) Trial in Worldwide (VAY736, VAY736 Placebo, CFZ533)
Active, not recruiting
- Systemic Lupus Erythematosus (SLE)
- VAY736
- +3 more
-
Ciudad Autonoma de Bs As, Buenos Aires, Argentina
- +31 more
Sep 19, 2022
Liver Transplant Rejection Trial in Worldwide (CFZ533, Tacrolimus - MMF - corticosteroids)
Active, not recruiting
- Liver Transplant Rejection
- CFZ533
- Tacrolimus - MMF - corticosteroids
-
Los Angeles, California
- +28 more
Jan 17, 2023
Hidradenitis Suppurativa Trial in Worldwide (CFZ533, Placebo to CFZ533, LYS006)
Recruiting
- Hidradenitis Suppurativa
- CFZ533
- +8 more
-
Orange Park, Florida
- +42 more
Jan 13, 2023
Rheumatoid Arthritis Trial in Taiwan, United States (CFZ533, Placebo)
Completed
- Rheumatoid Arthritis
- CFZ533
- Placebo
-
Anniston, Alabama
- +5 more
Dec 9, 2020
Myasthenia Gravis, Generalized Trial in Worldwide (Placebo, CFZ533)
Completed
- Myasthenia Gravis, Generalized
- Placebo
- CFZ533
-
Montreal, Quebec, Canada
- +14 more
Dec 9, 2020